The EPO published patent application EP3536693A1 for Takeda Pharmaceutical Company Limited on March 25, 2026. The application covers boronate ester compounds and pharmaceutical compositions, classified under C07F 5/02 (boron compounds). The designated states include AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR. IPC classifications include A61P 35/00 (anti-cancer) and A61P 29/00 (analgesic/anti-inflammatory).

This patent publication does not create new compliance obligations for pharmaceutical manufacturers or competitors. Entities developing similar boronate ester therapeutics should review the patent claims for freedom-to-operate concerns or licensing opportunities. No action is required from the patent applicant at this publication stage.